Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer-Reference-Cited by-同舟云学术

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer

Published:2013-07-09 Issue:9 Volume:62 Page:1521-1531
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Gulley James L.,Heery Christopher R.,Madan Ravi A.,Walter Beatriz A.,Merino Maria J.,Dahut William L.,Tsang Kwong-Yok,Schlom Jeffrey,Pinto Peter A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-013-1448-0.pdf

Reference46 articles.

1. Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J (2002) Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res 8:41–53

2. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099–1105. doi: 10.1200/JCO.2009.25.0597

3. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59:663–674. doi: 10.1007/s00262-009-0782-8

4. Madan RA, Gulley JL, Fojo T, Dahut WL (2010) Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15:969–975. doi: 10.1634/theoncologist.2010-0129

5. Madan RA, Mohebtash M, Schlom J, Gulley JL (2010) Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther 10:19–28. doi: 10.1517/14712590903321421

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The therapeutic impact of programmed death – 1 in the treatment of colorectal cancer;Pathology - Research and Practice;2024-07

2. Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer;Life;2023-07-01

3. Vaccinating against cancer: getting to prime time;Journal for ImmunoTherapy of Cancer;2023-06

4. Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials;Frontiers in Immunology;2023-03-07

5. A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance;European Urology Focus;2022-12